Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 Forward PE Ratio is 39.70 as of Sep. 01, 2026. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 71.26% on this metric.
WuXi XDC Cayman (STU:L74) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
WuXi XDC Cayman Forward PE Ratio Related Terms
WuXi XDC Cayman Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman Forward PE Ratio Chart
WuXi XDC Cayman Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
32.07
31.86
WuXi XDC Cayman Semi-Annual Data
2024-12
2025-06
2025-12
2026-06
Forward PE Ratio
32.07
28.84
31.86
28.67
STU:L74 vs TMO, DHR, NTRA: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
WuXi XDC Cayman (STU:L74) has a Forward PE Ratio of 39.70 as of Sep. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on WuXi XDC Cayman and its competitors. According to the industry distribution chart, WuXi XDC Cayman ranks #62 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 71.3%.
Is WuXi XDC Cayman's Forward PE Ratio too high?
WuXi XDC Cayman's current Forward PE Ratio is 39.70. The Medical Diagnostics & Research industry median Forward PE Ratio is 24.56. WuXi XDC Cayman's value of 39.70 is 61.6% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #62 out of 87 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #62 out of 87 companies for Forward PE Ratio. This places WuXi XDC Cayman in the lower half of its industry. The industry median Forward PE Ratio is 24.56. WuXi XDC Cayman's value of 39.70 is 61.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 24.56, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current Forward PE Ratio of 39.70 is 61.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 24.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current Forward PE Ratio is 39.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current Forward PE Ratio of 39.70. The current Forward PE Ratio is 39.70 and 61.6% above the Medical Diagnostics & Research industry median of 24.56. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current Forward PE Ratio is 39.70 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
